CrowdStrike reiterated its long-term ambition, which continues to anchor the model: reaching $10 billion in subscription ARR by fiscal 2031. Framed against today's run rate, this target assumes the ...
Relmada Therapeutics ( ($RLMD) ) has shared an announcement. On September 17, 2025, Relmada Therapeutics updated its corporate presentation, ...
Aera Therapeutics, a biotechnology company harnessing next-generation enabling delivery technologies and precision payloads to unlock the full potential of genetic medicines, today presented ...
Dye & Durham's experienced and refreshed nominees, are leading an orderly transition to a new CEO, supporting the focused and engaged senior leadership team and driving strong organic growth Engine's ...
The presentation follows PJT’s strong performance in Q3 2024, when the company reported a 17% year-over-year increase in revenue to $326 million. The firm’s shares closed at $135.35 on April 28, 2025, ...
The debt maturity profile is well-distributed, providing the company with financial flexibility and reducing refinancing risk: The company’s net debt-to-equity ratio of 1.28x is within management’s ...
The poster, titled "Study Design of a Phase 2a Double-Blind Placebo-Controlled Trial of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis," will outline the clinical trial design ...
HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback